FDA fast-track approval of belzutifan is a milestone in rare cancer therapy

Competing interests

C.A. and R.A.T. are members of the Pheochromocytoma and Paraganglioma (PPGL) Working Group of the European Network for the Study of Adrenal Tumors (ENS@T). R.A.T receives research funding from the Paradifference Foundation and Pheipas Association to support research on metastatic PPGL.

Comments (0)

No login
gif